Fintel reports that on March 21, 2025, Benchmark initiated coverage of Kamada (NasdaqGS:KMDA) with a Buy recommendation.

EMA advisors at the Committee for Medicinal Products for Human Use (CHMP) recommended Sandoz’s adalimumab Humira biosimilar under three brand names – Halimatoz, Hefiya and Hyrimoz. The firm ...

EU rules that all biosimilars are interchangeable The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have, meanwhile, published a statement confirming that all EU ...

Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite ...

Mumbai-based Kilitch Drugs Ltd plans to enter biosimilars and oral solids, including diabetic and weight-loss tablets, and is ...

Contract Development and Manufacturing Organizations (CDMOs) enhance drug discovery by providing essential services that ...

UCB, a global biopharmaceutical company, today announced positive data from studies involving its investigational pyrimidine nucleoside therapy, doxecitine (dC) and doxribtimine (dT), in people living ...

Godrej Properties Ltd has purchased ~10 acres of land in Yelahanka, Bengaluru to develop ~1.5 million square feet of saleable ...

The Reserve Bank of India has accorded its approval on March 21, 2025 for acquisition of shareholding of up to 100% of the ...